Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Latest Information Update: 05 Nov 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CHECKMATE-069
- Sponsors Bristol-Myers Squibb
- 13 Sep 2022 Results of pooled-analysis of immune checkpoint inhibitor (ICI) trials (CheckMate [CM] 066, 067, 069 & 511) presented at the 47th European Society for Medical Oncology Congress
- 19 Nov 2021 Status changed from active, no longer recruiting to completed.
- 21 May 2021 Results assessing Genetic susceptibility to immune-related adverse events among melanoma patients treated with ipilimumab from CTP: 212722, 232535 and 236250 presented at the 112th Annual Meeting of the American Association for Cancer Research